INTRODUCTION
Drug induced agranulocytosis (DIA), characterized by neutrophil count below 0.5x10 9 /l, is a dangerous adverse reaction that can be caused by almost all classes of medicaments.
Th e overall incidence of non chemotherapy DIA ranges from 2.6 to 10 cases per million patients exposed to drug per year [1] . Patients with such a severe neutropenia may initially be asymptomatic, although oft en proceed into severe life-threatening sepsis which can be fatal [2] . Medications such as antithyroid drugs, ticlopidine, clozapine, cotrimoxazole, are currently the typical causes of agranulocytosis. Clinical characteristics of patients with DIA are febrility, chills, oropharingeal infection with ulcerations and severe infections such as pneumonia and sepsis. With appropriate management, the mortality rate is currently estimated at 5-10% [3, 4] , but in elderly patients with comorbidities, the mortality rate can be still nowadays up to 20% [2, 5] .
We report our experience based on 15 patients with established criteria for agranulocytosis, who were treated with broad-spectrum antibiotic therapy and hematopoietic growth factors which helped survival of 14 patients.
METHODS AND RESULTS
In the study we analyzed clinical picture, laboratory data and outcome of 15 patients diagnosed with DIA at the Clinic of Hematology, Clinical Center Serbia in ten years period from 2006 to 2016 years.
Criteria for inclusion were neutrophil count below 0.5x10 9 /l, presence of fever and/ or clinical signs of infection, onset of agranulocytosis during treatment or within 7 days in case of previous intake of the same drug and no clinical features and more than 1.5x10 9 /l neutrophils in blood cell count, 1 month after drug discontinuation [4, 6] . Th e exclusion criteria were: existence of history of congenital neutropenia or immune neutropenia, no history of recent viral infection, suppression of bone marrow by recent chemotherapy, radiotherapy, and/or immunotherapy or development of an underlying hematological or malignant disease (infi ltration of bone marrow with malignant cells) [6, 7] . All 15 patients fulfi lled the international criteria for DIA (4, 5) .
We examined the following data: age; gender; clinical features; medical history and co-morbidities; clinical presentation; causative drugs, Nadir of white blood cell; bone marrow analysis; time to reach a neutrophil count exceeding 1.5x10 9 /l (hematological recovery); use of hematopoietic growth factors (HGF), fi nal outcome, and mortality rate. All patients had negative serological tests for human immunodefi ciency virus, hepatitis B and C virus, Epstein-Barr virus, cytomegalovirus, and parvovirus B19.
Median age of the study group was 36 years (range 25-61 year). Th e male/female ratio was 2/13. Underlying diseases were found in 10 (66.6%), consisting of hyperthyreosis in 7 (46.6% patients), mental disorders in 2 patients (13.3%) and 1 (6.6%) patient suff ering from perianal fi stula who for pain relief was receiving metamizole as a causative drug for agranulocytosis. At admission the clinical presentation were isolated fever in 4 (26.6%) patients, documented pneumonia in 4 (26.6%), non systemic infections, sore throats and acute tonsillitis in 5 (33.3%) patients and a septic shock in 1 (6.6%) and 1 (6.6%) patient was asymptomatic. Bacteriological examination was positive in one patient (Escherichia coli), the other one had Candida albicans infection in oropharyngeal cavity. Nadir median neutrophil count was 0.3x10 Table 1 . Criteria for idiosyncratic drug-induced agranulocytosis [4] [5] [6] tic erythroid changes in 1 (6.6%) and normal bone marrow fi nding in 4 (26.6%) patients. Th e single causative drug was strengthened in 13 cases and in two patients two drugs were suspected as a cause. Th e distribution of causative drugs in this cohort of patients were as follow: antityreoid drugs tiamazol and propylthiouracil in 7 patients, metamizol in 2, clozapine in 2 and paracetamol in 2 patients, diclofenac and ibuprofen at the same time in 2 patients.
Before admission 8 (53.3%) patients were submitted to oral antibiotics but febrility continued in all.
Aft er admission all patients were im- 4-15 days) . G-CSF administered subcutaneously in a fi xed dose of 300 μg/day, 48 h aft er DIA was diagnosed in 10 (66.6%) patients until the neutrophil count became over 1.5x10 9 /l. Clinical and laboratory characteristics of the patients are presented in Table 2 . Th e outcome was favorable in 14 patients. Aft er 5 months 1 (9.09%) patient died from acute leukemia. Th is patient had perianal fi stula and severe pain. He was given metamizole for pain relief aft er which he developed severe agranulocytosis. His white blood cell count was 0x10 9 /l. He was treated with broad spectrum antibiotics and G-CSF (which he received for 4 days). He completely recovered with normal white blood cells count but aft er 4 months he became malaise, he got haemorrhagic syndrome, febrility and on hematological survey an acute myeloid leukemia AML M2, Flt3/ITD +, NPM -was diagnosed. He died in aplasia 11 days aft er termination of induction chemotherapy. DISCUSSION DIA is extremely rare life-threating condition with annual incidence 3 to 16 cases per million population per year [2, 6, 7] . Th e number of fatal cases decreased during the last few decades. Th e main poor prognostic factors are: age over 65 years, neutrophil count at diagnosis of <0.1x109/l, development of severe septicemia and septic shock, as well as pre-existing comorbidities such as diabetes mellitus, cardiac failure and renal impairment [4, 8] .
Th e current defi nition of DIA is proposed by IAAAS and Benichu et al [6] . It is characterized by sudden onset and severe drop of neutrophil count below 0.5x10 9 /l. All our patients fulfi lled criteria for agranulocytosis, with median neutrophil count of 0.4x10 9 /l with complete recovery of white blood cells and neutrophils in all 14 cases aft er removal of causative agent and the treatment [4] [5] [6] . Th e drugs that most frequently caused agranulocytosis were changing during the time, from aminopyrine, pirazolone, anti-thyroid drugs to sulfasalazine, phenothiazines, semi-synthetic penicillins, procainamid, non-steroidal anti-infl ammatory drugs, aminopyrine derivatives, benzodiazepines, barbiturate, gold compounds, sulfonamides which are the most common causative agents of neutropenia and agranulocytosis in the world nowadays [9] [10] [11] [12] [13] . In our group of patients incriminated drugs were antithyroid medicaments, neuroleptics, analgetics, antipyretics and nonsteroidal antiinfl ammatory agents.
Th e occurrence of agranulocytosis with the use of antithyreoid drugs was noticed soon aft er their introduction in the treatment of hyperthyreosis. Th e incidence of agranulocytosis cased by propylthiouracil, methimazole and carbimazole is 0.1-0.37% of patients receiving this medication per year [12] . Antithyroid drug agranulocytosis oft en occurs during the fi rst 3 months of treatment, but it can occur even aft er a long period of treatment [10] .
Th e mechanisms of neutropenia and agranulocytosis may be immune mediated or can be the result of direct damaging eff ect of used drug on granulocytic cell line [13] . It may occur as an idiosyncratic reaction, most often secondary through diff erent mechanisms accelerating immune-mediated destruction. Some drugs act as haptens (aminopyrine, penicillin, gold compaunds) inducing antibody formation against neutrophils [13, 14] . Circulating immune complexes may be formed and bind to neutrophils causing their destruction [13] . Clozapine is an example of drug which accelerates the process of apoptosis of neutrophils, not directly, but rather aft er bioactivation and formation of reactive nitrenium ion [15] which covalently binds to cellular proteins and induces neutrophil cell toxicity. Beta-lactam antibiotics at high concentrations induce inhibition of growth of colony-forming units of granulocytes and macrophages [16] . Ticlopidine acts over direct reversible cytotoxity for hemopoietic progenitor stem cells [17] . Th ere are some drugs for which genetic risk factors have been recently identifi ed. Genetic analysis of human leukocyte antigen genotyping and genome-wide association study in patients with antithyroid drug-induced agranulocytosis demonstrated presence of two independent susceptibility loci HLA-B*38:02 and HLA-DRB1*08:03 as the major genetic determinants of those patients [18] . In white European population, antithyroid drug-induced agranulocytosis was associated with HLA-B*27:05 and with other single nucleotide polymorphisms on chromosome 6. In the future, carriers of these variants could be off ered alternative treatment for hyperthyroidism [19] . Th is results could be useful for antithyroid DIA and potentially for agranulocytosis caused by the other drugs.
Th e clinical characteristics of agranulocytosis in our cohort of patients was similar to other series [2, 20] . Our patients had less severe infections, like septicemia, septic shock probably due to early antibiotic therapy before hospitalization. Th at might also be the reason that all our patients survived. It should also be noted that our study group was young (median age 36 years) and without serious comorbidities like diabetes mellitus, rheumatic disease, cardiac failure or respiratory insuffi ciency.
Th e most common site of infections in DIA are mucous membranes, oral cavity, presenting as oral ulcerations, pharyngitis, ulceronecrotic pseudomembrane angina, oedema of regional lymph nodes and swelling. Manifestations of infection on the skin are rash, ulcerations and abscesses. Perirectal infection are also common. Systemic infections of lungs and genitourinary tract may be fatal if they spread to blood stream. A jaundice, as a sign of septic hepatitis, is a very serious complication announcing fatal outcome. But in modern time the treatment of infections as early as possible with broad spectrum antibiotics and G-CSF reduces the risk of fatal outcome. Th e pathogens causing infections are bacteria, but also fungi were increased in incidence in the last years. Infected patients may develop toxic shock with fever, hypotension, diff use rash and respiratory distress syndrome with fatal outcome.
CONCLUSION
In conclusion, in the occurrence of neutropenia, febrility, and signs of infl ammation during any drug treatment a DIA should be immediately considered. Any drug as a presumed causative agent should be discontinued for ever. Management of bacterial and fungal infections with broad spectrum antibiotics and hematopoietic growth factors may reduce mortality, enable complete hematological recovery and reduce days of hospitalization. A numerous medicaments are emerging as possible causative agents of DIA so that every medication should be closely followed up and in the case of neutropenia or DIA it must be removed for ever.
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